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DC maturation
 
DCs are “immunological sensors” that
reside throughout the body in an imma-
ture form. Immature DCs can capture
invading microbes, which provide a
source of antigens and ligands for
Toll-like receptors (TLRs) that trigger
a process of maturation and/or differ-
entiation. The mature DCs migrate to
draining secondary lymphoid tissues,
present the captured antigen, and up-
regulate costimulatory molecules and
cytokines. Mature DCs both initiate
and direct T and B cell responses.
During the meeting, it was reported
that a combination of TLR agonists
that mobilize both MyD88 and TRIF
adaptors for TLR signal transduction—
such as the TLR4 ligand lipopoly-
saccharide (LPS) with the synthetic
viral RNA mimic and TLR7 ligand
R848, or alternatively the TLR3 li-
gand poly IC with R848—synergize
to induce elevated and sustained inter-
leukin (IL)-12 production by human
DCs, enhancing T helper (Th) type 1
responses in vitro (Federica Sallusto,
 
Mechanisms of type I IFN production 
in DCs
 
Type I interferon (IFN) is especially
important for antiviral immunity. Al-
though various kinds of cells including
macrophages, fibroblasts, or conven-
tional DCs can also produce type I
IFN, a unique DC subset, the plasma-
cytoid dendritic cells (pDCs), is the
most potent type I IFN producer.
New insights into the mechanisms
controlling type I IFN production
were presented during the meeting.
Giorgio Trinchieri (Bethesda, MD) re-
ported that pDC-depleted mice or
mutant mice lacking pDCs showed se-
verely decreased production of type I
IFN in certain viral infections, which
depended mainly on TLR7 and TLR9,
which recognize ssRNA and un-
methylated CpG DNA, respectively.
MyD88, an adaptor molecule for both
TLR7 and TLR9 signaling, was shown
by Tadatsugu Taniguchi (Tokyo, Ja-
pan) to associate directly with the
transcription factor, IRF-7, which is
essential for IFN-
 
 
 
 induction (5).
However, type I IFN can also be in-
duced in non-pDCs by viruses in a
TLR-independent manner (Christine
Biron, Providence, RI). It was also re-
ported that apoptotic cells can trigger
type I IFN production in a TLR-inde-
pendent manner, although the full
mechanism for this was unclear (Kasper
Hoebe, La Jolla, CA). Insight into in-
tracellular components of TLR-inde-
pendent pathways for induction of
type I IFN was provided by Hiroki
Kato (Osaka, Japan), who found that
double-stranded RNA stimulated an
RNA helicase (RIG-I) to induce type
I IFN in fibroblasts and myeloid DCs
(mDCs). RIG-1 induced type I IFN
by activating IFN regulatory factor
(IRF)-3 via I
 
 
 
B kinase–related kinases.
An overview of type I IFN production
in DCs based on these new findings is
shown in Fig. 1.
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Bellinzona, Switzerland) (1). TLR sig-
nals were also reported to alter the ex-
pression of Notch family ligands on DCs,
up-regulating Delta-4 and down-
regulating Jagged1, a finding that
confirms earlier mouse data (2). Delta-
4–expressing DCs promoted Th1 re-
sponses, whereas Jagged promoted Th2
responses. Thus, modulation of Notch
ligands on DCs may be an important
mechanism by which TLR matura-
tional signals push Th responses in the
Th1 or Th2 direction.
Another type of microbial recogni-
tion occurs via C-type lectin receptors
(CLRs), which primarily mediate the
uptake of microbial antigens. Carl Figdor
(Nijmegen, Netherlands) demonstrated
that DC-SIGN binds numerous patho-
gens and is organized in well-defined
membrane microdomains (3). The CLR
Dectin-1, which binds 
 
 
 
-glycans and
zymosan from fungi, induces TNF and
IL-12 production (Siamon Gordon, Ox-
ford, UK). These fungal products are
recognized by DCs through both TLR2
and Dectin-1, and TNF production has
been shown to be dependent on the TLR
signaling adaptor MyD88. Caetano Reis
e Sousa (London, UK) showed that zy-
mosan binding to Dectin-1 on DCs ad-
ditionally induced high levels of IL-10
and IL-2, which required Syk kinase
(4). In contrast, IL-12 production was
dependent on MyD88 and independent
of Syk. A fine balance between these
signaling pathways in response to fun-
gal products such as zymosan will un-
doubtedly determine the outcome of
an immune response to fungi.
 
The fast-moving field of dendritic cell (DC) biology is hard to keep pace with. 
Here we report on advances from the recent Keystone Symposium, “Dendritic 
Cells at the Center of Innate and Adaptive Immunity,” organized in Vancouver, BC 
on Feb. 1–7, 2005 by Anne O’Garra, Jacques Banchereau, and Alan Sher. New 
insights into the molecular mechanisms of DC function and their influence on 
immune regulation, their role in infectious and autoimmune disease, and new 
clinical applications are highlighted.
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Th1/Th2 and regulatory responses
 
DCs exposed to certain microenviron-
mental stimuli are known to promote
the differentiation of CD4
 
 
 
 T cells into
Th1, Th2, or T regulatory (T reg) cell
subsets. IL-10 production by DCs is
known to favor Th2 and T reg cell de-
velopment, and IL-12 production is
required for Th1 cell development.
However, little is known about the in-
tracellular signaling pathways within
DCs that underlie differential cytokine
secretion. Although most TLR signal-
ing in DCs is known to prime Th1 re-
sponses, Bali Pulendran (Atlanta, GA)
has previously shown that signaling
through TLR2 induced DCs to secrete
IL-10, by a mechanism dependent on
the MEK kinase ERK, without secre-
tion of IL-12p70, and thus favored Th2
responses (6). Similarly, work from
Anne O’Garra’s laboratory (National
Institute for Medical Research, London,
UK) showed that a delicate balance in
signaling through ERK determines IL-
10 versus IL-12 production by DCs.
Pulendran also showed that zymosan (a
ligand for TLR2, TLR6, and Dectin-1)
stimulates DCs to robustly secrete IL-10
(which appeared to be ERK dependent)
but not inflammatory cytokines, both in
vitro and in vivo.
A potential new mode of DC self-
regulation to control Th1 responses
was proposed by Marika Sarfati (Mont-
real, Canada). Ligation of CD47 on
DCs by thrombospondin-1 (TSP-1;
also produced by DCs) altered DC
maturation and negatively regulated
Th1 responses (7). TSP-1 production
by immature DCs was enhanced upon
activation and may thereby act as an
autocrine “deactivator.” Accordingly,
 
CD47
 
 
 
/
 
 
 
 DCs displayed an activated
phenotype, produced more IL-12, and
thereby induced enhanced Th1 re-
sponses. Future work will examine if
 
CD47
 
 
 
/
 
 
 
 mice are prone to autoim-
munity, as expected.
 
DC cell biology
 
The efficiency of antigen presentation
on MHC class II by DCs correlates
with their low levels of lysosomal pro-
teases, which allows antigen persistence
(8) (Ira Mellman, New Haven, CT). It
remains to be defined how DCs are able
to cross-present exogenous nonreplicat-
ing antigens for presentation on MHC
class I. The loading compartment may
be either the endoplasmic reticulum
(ER) or a mixed phagosome-ER com-
partment, a concept which had drawn
much attention recently (9, 10) and was
strongly challenged by Mellman who
has failed to find evidence for phago-
some-ER fusion by several approaches.
In a friendly discussion, Sebastian
Amigorena (Paris, France) suggested
that Mellman’s inability to find fusion
of GFP-tagged ER resident proteins
with phagosomes might be explained
by a low sensitivity of his detection
method. Amigorena focused on the
role of Rab27a in cross-presentation.
Rab27a, a GTP-binding protein, which
interacts with myosins and mediates ac-
tin binding, is expressed in DC phago-
somes and MHC class II endocytic
compartments. Rab27a deficiency leads
to enhanced protein degradation, high
phagosome acidification, and a delay in
phagosome fusion to the lysosome, all
of which hamper cross-presentation.
 
DC subsets and plasticity
 
DCs can develop along two pathways,
CD11c
 
 
 
 mDCs (also called conven-
tional DCs) and pDCs. mDCs have
long been known to include distinct
subsets such as Langerhans cells and in-
terstitial (dermal) DCs in humans and
CD8
 
 
 
 and CD8
 
 
 
 DCs in mice. Jacques
Banchereau (Dallas, TX) extended
mDC diversity into a wider rainbow of
mDC subsets. He showed that in vitro
different cytokines, such as IFN
 
 
 
/
 
 
 
,
IL-15, IL-4, and TNF, skew the differ-
entiation of monocytes, which are po-
tential precursors of mDCs, into differ-
ent DC subtypes. These subtypes have
both common and unique properties
and may ultimately shape the type of T
cells that respond in vivo upon micro-
bial invasion. The cytokines produced
by microbe-activated cells (pDCs, ke-
ratinocytes, mast cells) will determine
the type of DCs that the monocyte dif-
ferentiates into. Yong-Jun Liu (Hous-
ton, TX) showed that the cytokine
thymic stromal lymphopoietin (TSLP)
activated mDCs causing them to polar-
ize T cells, leading to an inflammatory
Th2 response characterized by TNF
expression. However, in the thymus,
Figure 1. Recognition of viral infection for induction of type I IFNs in conventional and 
plasmacytoid DCs. In pDCs, viral infection is recognized by TLRs, leading to type I IFN induction. 
Non-pDCs are suggested to utilize a TLR-independent system.
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TSLP produced by Hassal’s corpuscles
activated DCs to polarize CD4
 
 
 
CD8
 
 
 
thymocytes into CD4
 
 
 
 CD25
 
 
 
CD8
 
 
 
regulatory T cells.
Elina Zuniga (La Jolla, CA) showed
that infection with LCMV induces a
proportion of immature bone marrow
pDCs to differentiate into mDCs (11).
This claim was based on down-regula-
tion of all known pDC markers studied
(B220, Ly6C, and 120G8), up-regula-
tion of CD11c and CD11b (a prototype
mDC marker), enhanced antigen-pre-
senting capacity, and the up-regulation
of TLR3 and TLR4 expression, which
enabled responsiveness to LPS (a prop-
erty of mDCs not shared by pDCs).
Nonetheless, this finding was met with
skepticism by Jacques Banchereau who
argued that morphological changes and
receptor modulation—well-known char-
acteristics of DCs—might not equate to
lineage infidelity.
 
DC–T cell engagement in vivo
 
With the advent of new imaging tech-
nology, it is becoming possible to wit-
ness how DC and T cells interact in
vivo, which will undoubtedly provide
new insights on these interactions dur-
ing an immune response. Michel Nus-
senzweig (New York, NY) and Ronald
Germain (Bethesda, MD), each pre-
sented movies and images of DC–T cell
interactions in the lymph nodes of liv-
ing mice. Germain demonstrated by in-
travital two-photon microscopy the
ménage à trois between DCs, CD4
 
 
 
,
and CD8
 
 
 
 T cells. In the course of pro-
ductive immune responses, the antigen-
specific T cells establish interactions
with DCs that can last for several hours.
Amigorena, also using two-photon mi-
croscopy, failed to find stable interac-
tions between DCs and CD8
 
 
 
 T cells
during the induction of tolerance. Nus-
senzweig contested this finding, as he
observed that antigen-specific T cells
stopped for prolonged interaction with
the DC whether in the course of toler-
ance or immunity. He found that in the
steady-state most lymph node DCs are
entangled in an extensive sessile net-
work. The DC network surrounds the
B cell follicles, extends into the T cell
zones, and is particularly dense in the
border between the T and B cell folli-
cle, where T cell–dependent immune
responses are initiated. Mature DCs,
which migrate into lymph nodes from
tissues, eventually integrate into the
network (12). Russell Salter (Pitts-
burgh, PA) showed that myeloid-lin-
eage DCs and monocytes can be trig-
gered to flux calcium by mechanical
contact with a microprobe, and that the
signal can be propagated within seconds
to other cells at distances up to a hun-
dred microns away. This communica-
tion occurred via membranous connec-
tions called tunneling nanotubules
(TNTs), indicating that within the DC
network TNTs might permit transmis-
sion of signals between cells. These
findings regarding DC–T cell interac-
tions are illustrated in Fig. 2.
Marc Jenkins (Minneapolis, MA)
showed that antigen injected intrader-
mally is delivered to lymph nodes in
two waves. A recombinant fluorescing
antigen first diffused through lymphatic
vessels into the subcapsular sinus and
conduit network, reaching the resident
DC network within 30 minutes, which
presents the processed antigen within 3
hours. In the second wave, DCs that
had acquired antigen at the injection site
delivered antigen into the T cell areas
by 18 hours (Fig. 2). It is thought that
resident and migratory DCs educate T
cells to acquire different functions.
 
DCs in autoimmunity and allergy
 
Since DCs are critical in initiating and
perpetuating the class of the immune
response and cytokine production in
response to antigens, one might expect
that alterations of DC homeostasis
might determine autoimmune and al-
lergic pathologies. Fiona Powrie (Ox-
ford, UK) showed that in 
 
Rag
 
 
 
/
 
 
 
 mice
CD11c
 
 
 
CD11b
 
 
 
 DCs activated with
CD40-specific antibody induced coli-
tis and systemic wasting disease. Sys-
temic wasting was triggered by produc-
Figure 2. Two waves of antigen delivery. Antigen administered subcutaneously is delivered in 
two successive waves to the draining lymph node, and presented by different DCs which initiate 
different effector functions.
 
20050566  Page 7  Wednesday, June 22, 2005  10:41 PM 
DENDRITIC CELLS, VANCOUVER, BC, FEBRUARY 1–7, 2005 | Klechevsky et al.
 
8
 
tion of IL-12 and could be inhibited by
IL-12 p40-specific antibody, but local
inflammation was induced by IL-23
production, since treatment with anti-
p19 abrogated local disease. This im-
plies that cytokine antagonists might be
useful interventions in these diseases.
Overproduction of type I IFNs has
been associated with some autoimmune
disease states such as systemic lupus
erythematosus (SLE). Virginia Pascual
(Dallas, TX) reported that certain ar-
thritis patients develop an SLE-like syn-
drome during anti-TNF treatment (13).
Gene expression profiles in these pa-
tients show highly up-regulated expres-
sion of IFN-inducible genes, which
were similar to those up-regulated in
SLE patients. Virus-induced IFN-
 
 
 
 was
suppressed by TNF in vitro and aug-
mented by anti-TNF antibody. Based
on these results, Pascual proposed that
an imbalance between TNF and IFN-
 
 
 
production might cause SLE in anti-
TNF–treated rheumatoid arthritis pa-
tients. Cross talk between DCs and
non-DCs could be important for type I
IFN production both in physiologic
and pathologic conditions (13). Finally,
Pascual reported a spectacular improve-
ment when children suffering from a
devastating form of juvenile arthritis,
who failed to respond to anti-TNF
treatment, were treated with an IL-1
 
 
 
/
 
 
 
antagonist (14).
A pathogenic role for pDCs and
IFN
 
 
 
 (15) in human psoriasis was sug-
gested by Michel Gilliet (Houston,
TX). This skin disease is characterized
by chronic relapses and is triggered by
factors such as infection, stress and
drugs. Gilliet showed that precursors of
pDCs infiltrated the skin of psoriasis
patients and were activated to produce
IFN
 
 
 
 at an early stage of the disease
(16). Blocking IFN
 
 
 
 signaling and/
or production prevented induction of
psoriasis in a model in which human
skin from psoriatic patients was trans-
planted into mice.
In a mouse model of allergic asthma,
capture and presentation of an inhaled
protein by airway DCs was shown to
lead to T cell tolerance (Bart Lam-
brecht, Rotterdam, Netherlands) (17).
pDCs maintained this tolerance by sup-
pressing the development of Th2 cyto-
kine responses. It was not clear whether
pDCs mediated this effect by inducing
Th1 cytokines, type I IFNs, or IL-10
expression, all of which could result in
down-regulation of allergic responses.
However, mDC are essential for induc-
ing effector Th2 responses (17). Expo-
sure of human respiratory tract DCs to
granulocyte-macrophage colony-stimu-
lating factor, previously reported to be
released by respiratory cells in response
to allergens, was shown to activate DCs
to support Th2 cell differentiation (Al-
exander Faith, London, UK).
 
From DC and NK cells to DCs in infection
 
A new appreciation of DCs interactions
with NK cells was one of the highlights
of this meeting. Early IL-2 responses
from bacteria-stimulated DCs contribute
to activation of NK cells (18). In addi-
tion, DCs activated with TLR ligands
have been shown to induce an early in-
flux and activation of NK cells in the
lymph node and to be important for the
development of Th1 responses (19).
Nicolas Glaichenhaus (Valbonne, France)
extended our understanding of NK–DC
interactions in vivo with beautiful two-
photon images of NK cells in the lymph
nodes: 80% of these cells were located in
the outer paracortex near the lymphatics
and close to DCs. In the steady-state, NK
cells moved slowly but were seen to
crawl over the DCs making long lasting
(
 
 
 
20 minutes) contact. During infection
with 
 
Leishmania major
 
, antigen-specific T
cells were relocated to the outer paracor-
tex of the lymph node. However, NK
cell distribution, colocalization with DCs,
and the speed at which they moved were
not changed.
Alan Sher (Bethesda, MD) has been
searching for single TLR ligands re-
sponsible for the IL-12 production by
CD8
 
 
 
 DC stimulated with soluble
 
Toxoplasma gondii
 
 antigen (STag). In
addition to cyclophilin, which had
been previously identified as a ligand of
CCR5 (20, 21), Sher and colleagues
identified another STag protein, pro-
filin, which was shown to signal through
TLR11 and induce large amounts of
IL-12 in CD8
 
 
 
 
 
 DCs. 
 
Tlr11
 
 
 
/
 
 
 
 mice
showed decreased IL-12 production in
response to STag. These results impli-
cate TLR11 as a receptor for apicom-
plexan protozoan parasites and for IL-
12 production by DCs (22).
A new population of DC-like cells,
whose function remains a mystery, was
identified in other infections in mice.
Malin Sundquist (Goteborg, Sweden)
described large numbers of CD11c inter-
mediate CD11b
 
 
 
 DCs in mesenteric
lymph nodes of mice infected orally with
 
Salmonella
 
. Jean Langhorne (London,
UK) reported a large increase of DCs
with a similar phenotype in the spleen of
mice infected with malaria.
Human papilloma virus infection
(HPV) is thought to be the causative
agent for most cases of cervical cancer.
W. Martin Kast (Los Angeles, CA) has
found a possible mechanism for evasion
of T cell immunity to HPV (23).
Langerhans cells at the site of infection
did not elicit virus-specific immune re-
sponses, and Langerhans cells incubated
with HPV virus-like particles in vitro
up-regulated PI3K, which were previ-
ously shown to affect cytokine gene
regulation. However, when PI3K path-
ways were blocked, Langerhans cells
induced virus-specific T cell responses
in vitro. Thus, HPV may prevent the
priming of antiviral T cell responses by
inhibiting Langerhans cell activation
and/or migration.
In addition to DCs, innate viral
recognition by radioresistant cells, pos-
sibly epithelial cells, is also involved in
establishing Th1 immunity against viral
infection (Akiko Iwasaki, New Haven,
CT) (24).
 
TLR agonists and antagonists in vaccines 
and therapy
 
Small synthetic agonists of some TLRs
can be easily manufactured. Robert
Coffman (Dynavax, Berkeley, CA)
found that short oligonucleotide TLR9
agonists coupled to antigen activate
DCs, thereby increasing antigen uptake
and providing a strong adjuvant effect.
Coffman reported that pulmonary ad-
ministration of this TLR9 agonist in a
mouse model of allergic asthma led to
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specific inhibition of the Th2 response
to subsequent allergen challenge. Coff-
man also described a novel antagonist
that inhibited TLR7, 8, and 9 stimula-
tion and IFN-
 
 
 
 production by pDCs,
which suggested its use as a potential
therapy for SLE.
 
DC therapy and immunomonitoring
 
DCs generated in vitro by culturing ei-
ther monocytes or CD34
 
+
 
 hematopo-
ietic progenitor cells are considered
promising therapeutic vaccines in can-
cer. Gerold Schuler (Erlangen, Ger-
many) presented the results of the first
phase III randomized clinical trial of
DC vaccination in stage IV metastatic
melanoma patients. He found that of
the patients who received the DC vac-
cine, those who enjoyed a better health
status or expressed a particular HLA
haplotype (A2
 
+
 
/B44
 
 
 
) survived signifi-
cantly longer. Thus, overall health sta-
tus and HLA type may influence the
success of active immunotherapy, and
these parameters should be considered
in the design of future vaccines. Hideki
Ueno (Dallas, TX) presented EPI-
MAX, a novel high throughput strat-
egy for predicting and monitoring the
immune response of vaccinated pa-
tients. By simultaneously analyzing T
cell proliferation and production of
multiple cytokines in response to pools
of peptides from overlapping libraries,
it was possible to accurately define the
specificity and the type of T cell re-
sponses in patients, before or after DC
vaccination. This allowed for the mon-
itoring of multiple types of tumor anti-
gen-specific T cells which may affect
the outcome of the vaccine in cancer.
In vivo targeting of antigen to DCs
might eventually replace vaccination
with ex vivo–generated, antigen-loaded
DCs. A single dose of an antibody spe-
cific for the DC-specific lectin DEC-
205 fused to HIV-gag induced efficient
CD4
 
 
 
 T cell immunity against HIV-
gag protein that protected mice against
a challenge with recombinant vaccinia-
gag virus (Ralph Steinman, New York,
NY). They anticipate that this will form
the basis of future vaccines in cancer
and infectious disease therapies.
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